Reports and Findings
Research
Development of a longer acting formulation of Penicillin G for the treatment and prevention of acute rheumatic fever and rheumatic heart diseaseJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@thekids.org.au Institute Director; Head, Strep A Translation; Co-Founder of REACH Professor Carapetis is
Research
Developing a human challenge model of GAS infectionJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@thekids.org.au Institute Director; Head, Strep A Translation; Co-Founder of REACH Professor Carapetis is
Research
Defining target penicillin concentrations for subsequent studies of a reformulated long-acting benzathine penicillin prototypeJonathan Tim Carapetis AM Barnett AM MBBS FRACP FAFPHM PhD FAHMS PhD Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH Head, Strep A Pathogenesis and Diagnostics 08 6319 1000 contact@thekids.org.au timothy.barnett@thekids.org.au
Research
Defining Group A Streptococcus interaction with the tonsil epithelium to inform vaccine developmentA vaccine that prevents the initial attachment of Strep A to the tonsils would reduce the incidence of Strep throat and severe diseases that result.
Research
Controlled Human Infection for Penicillin Against Streptococcus pyogenes – a double blinded randomised trail (The CHIPS trial)In Australia, RHD-related death and disability is the leading driver of cardiovascular inequality between Indigenous and non-Indigenous Australians.
Research
Coalition to Advance Vaccines Against Group A Streptococcus (CANVAS): A Trans-Tasman Initiative Against Rheumatic FeverInvestigators: Amy Baker, Jeffrey Cannon, Jonathan Carapetis, Katherine Gray, Yue Wu External collaborators: University of Auckland: Nikki Moreland, John Fraser, Diana Lennon Otago University: Michael Baker Griffith University: Michael Good, Michael
Research
Burden of rheumatic heart disease (RHD) and impact of prevention strategies: comprehensive evidence to drive the RHD EndgameJonathan Judy Rosemary Carapetis AM Katzenellenbogen Wyber AM MBBS FRACP FAFPHM PhD FAHMS BSc (Occ Ther) BSc Hons (Epidemiol) MSc PhD MBChB MPH FRACGP PhD Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH Honorary Research
Research
BPG Formulation Preferences Study: Exploring patient, family and clinician reformulations preferences for BPGJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@thekids.org.au Institute Director; Head, Strep A Translation; Co-Founder of REACH Professor Carapetis is
Research
Towards a diagnostic test for rheumatic feverGlenn Jonathan Michael Pat Tim Tobias Pearson Carapetis AM Serralha Holt Barnett Kollmann BA (Education) PhD Candidate AM MBBS FRACP FAFPHM PhD FAHMS PhD, DSc, FRCPath, FRCPI, FAA PhD PhD, M.D., SFUW Director of First Nations Strategy and Leadership
Research
Acceptability of sonicated versus unsonicated reconstituted (powdered) benzathine penicillin G for rheumatic fever prophylaxisPowdered benzathine penicillin G (BPG) crystals vary widely in size and shape and are larger and less uniform than crystals found in pre-mixed suspensions of BPG like Bicillin ® L-A.